When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MYOV - Myovant's Solid Progress Towards A Few Approvals Should Not Be Ignored
Myovant Sciences Ltd.
Myovant (MYOV) announced that it had achieved positive results from the LIBERTY 2 phase III study using a once-daily relugolix combination therapy to treat women with uterine fibroids. The biotech had already met on the primary endpoint for its first phase III study known as LIBERTY 1. This will allow Myovant to file an NDA for potential approval of the relugolix combination treatment by the end of 2019. Besides using its combination treatment for uterine fibroids, it is also exploring relugolix alone in two phase III studies for women with endometriosis. Results from